Compare Crocs, Inc. (CROX) vs TG Therapeutics Inc (TGTX) Price & Performance

Crocs (CROX) trades at $130.55, down 5.53% amid negative sentiment from recent tax haven scrutiny and a weak Q3 outlook. The stock shows strong fundamentals with three consecutive earnings beats and attractive valuation metrics (P/E 11.69, P/S 1.67). Technical indicators are mixed with bearish signals but key support at $128. Revenue remains stable at $4B+ with robust gross margins of 57.47%.

Despite near-term headwinds, CROX offers value with analyst consensus target of $140.43 (7.6% upside). Risks include tax regulation scrutiny, HEYDUDE brand weakness, and tariff pressures. The company maintains strong profitability metrics (ROE 42.3%) and raised full-year 2026 guidance, supporting long-term growth potential.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.